Subcutaneous Self Injection Markets to 2026


Several pharma and biotech companies are embracing the combination product concept for subcutaneous injectables and using it to differentiate their drug offerings, while others are opting for a minimalist approach. Interferons for treating Multiple Sclerosis are primarily marketed in prefilled syringes, while human growth hormone indicated for hormone deficiency in children is supplied almost exclusively in reusable, custom-designed variable dose pen injectors. Even within a particular therapeutic drug class, strategic variations are evident.



A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application. As these combination products have proliferated, so too have product strategies.